AIM:To explore the efficacy and safe-ty of two drugs in diagnosed idiopathic membra-nous nephropathy(IMN).METHODS:A retrospec-tive study was conducted on 113 patients diag-nosed with IMN by renal biopsy or PLA2R antibody positive at the department of nephrology,yijishan hospital,wannan medical college from november 2019 to July 2024,of whom 55 received cyclophos-phamide treatment and 58 received rituximab treatment,and follow-up was ≥6 months.RESULTS:At 6 months,38 patients(69.09％)in the cyclophos-phamide treatment group and 36 patients(62.07％)in the rituximab treatment group had achieved a combined response(complete or partial response).At 12 and 18 months,there was no statistical differ-ence in the combined response rate between the two groups(70.83％vs.83.87％,P=0.186 and 73.68％vs.73.68％,P=1.000),but at 12 months,the combined response rate in the rituximab group was higher than that in the cyclophosphamide group.In IMN patients with eGFR＜60 mL/(min·1.73 m2),rituximab significantly improved renal function(P=0.008).Over the entire follow-up peri-od,the total number of adverse events was higher in the cyclophosphamide group than in the ritux-imab group(57 vs..45),and the incidence of non-serious adverse events was higher than in the ritux-imab group(P=0.039).CONCLUSION:The efficacy of rituximab in the treatment of IMN is not inferior to that of cyclophosphamide,and it has better safety.Rituximab improved renal function better than cy-clophosphamide in patients with eGFR＜60 mL/(min·1.73 m2)IMN.

AIM:To explore the efficacy and safe-ty of two drugs in diagnosed idiopathic membra-nous nephropathy(IMN).METHODS:A retrospec-tive study was conducted on 113 patients diag-nosed with IMN by renal biopsy or PLA2R antibody positive at the department of nephrology,yijishan hospital,wannan medical college from november 2019 to July 2024,of whom 55 received cyclophos-phamide treatment and 58 received rituximab treatment,and follow-up was ≥6 months.RESULTS:At 6 months,38 patients(69.09％)in the cyclophos-phamide treatment group and 36 patients(62.07％)in the rituximab treatment group had achieved a combined response(complete or partial response).At 12 and 18 months,there was no statistical differ-ence in the combined response rate between the two groups(70.83％vs.83.87％,P=0.186 and 73.68％vs.73.68％,P=1.000),but at 12 months,the combined response rate in the rituximab group was higher than that in the cyclophosphamide group.In IMN patients with eGFR＜60 mL/(min·1.73 m2),rituximab significantly improved renal function(P=0.008).Over the entire follow-up peri-od,the total number of adverse events was higher in the cyclophosphamide group than in the ritux-imab group(57 vs..45),and the incidence of non-serious adverse events was higher than in the ritux-imab group(P=0.039).CONCLUSION:The efficacy of rituximab in the treatment of IMN is not inferior to that of cyclophosphamide,and it has better safety.Rituximab improved renal function better than cy-clophosphamide in patients with eGFR＜60 mL/(min·1.73 m2)IMN.

AIM:To investigate the etiological distribution and drug resistance of bacterial infection in inpatients of nephrology department and to provide evidence for the selection of antibiotics for clinical treatment of bacterial infection. METHODS:The data of positive pathogenic bacteria were collected from the samples of inpatients of the department of nephrology of Yijishan Hospital of Wannan Medical College from January 2016 to June 2019. RESULTS:A Total of 286 strains of bacteria were cultured, which were mainly from the respiratory tract infection and the urinary tract infection. Gram-negative bacteria accounted for 89.51% and gram positive bacteria accounted for 10.49%. Among Gram-negative bacteria, Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae were the top three bacteria detected in Enterobacteriaceae, while Pseudomonas aeruginosa and Acinetobacter baumannii were the top two bacteria detected in non-fermentative negative bacilli; The detection rate of extended-spectrum β-lactamase-producing bacteria (ESBLs) was 32.87%, which were mainly Escherichia coli and Klebsiella pneumoniae. The resistant rates of Escherichia coli and Klebsiella pneumoniae in ESBLs to aztreonam and ceftriaxone were 83.8% and 100% respectively; The resistance rate of Carbapenem resistance strains was 6.29%. Among Gram-positive bacteria, Staphylococcus aureus was the most common, and the resistance rate of methicillin-resistant Staphylococcus aureus (MRSA) was 4.89%. CONCLUSION:ESBLs-producing Escherichia coli and Klebsiella pneumoniae had high detection rates among isolated bacterial pathogens in the department of nephrology.

OBJECTIVETo compare two equations for calculating glomerular filtration rate (GFR) in the evaluation of the prevalence of chronic kidney disease (CKD) and the risk factors of CKD in urban healthy population.

METHODSA total of 40377 subjects (24164 males and 16213 females) participated in this study. Body height, weight and blood pressure were measured, and morning urine and venous blood samples were collected for routine urine and blood tests with measurements of blood glucose, total cholesterol, high density lipoprotein (HDL), low-density lipoprotein (LDL), creatinine and uric acid.

RESULTS AND CONCLUSIONUsing Japanese CKD Epidemiology Collaboration (J-EPI) equation and Chinese modified Modification of Diet in Renal Disease (C-MDRD) equation, the prevalence of CKD calculated was 3.9% and 6.3% in this population, respectively. The independent risk factors of CKD included an age over 60 years, high uric acid, and high blood glucose.

Adolescent ; Adult ; Age Distribution ; Aged ; Aged, 80 and over ; Female ; Glomerular Filtration Rate ; Humans ; Male ; Middle Aged ; Physical Examination ; Prevalence ; Renal Insufficiency, Chronic ; epidemiology ; physiopathology ; Risk Factors ; Sex Distribution ; Young Adult

Objective To compare two equations for calculating glomerular filtration rate (GFR) in the evaluation of the prevalence of chronic kidney disease (CKD) and the risk factors of CKD in urban healthy population. Methods A total of 40377 subjects (24164 males and 16213 females) participated in this study. Body height, weight and blood pressure were measured, and morning urine and venous blood samples were collected for routine urine and blood tests with measurements of blood glucose, total cholesterol, high density lipoprotein (HDL), low-density lipoprotein (LDL), creatinine and uric acid. Results and Conclusion Using Japanese CKD Epidemiology Collaboration (J-EPI) equation and Chinese modified Modification of Diet in Renal Disease (C-MDRD) equation, the prevalence of CKD calculated was 3.9%and 6.3%in this population, respectively. The independent risk factors of CKD included an age over 60 years, high uric acid, and high blood glucose.

Objective To compare two equations for calculating glomerular filtration rate (GFR) in the evaluation of the prevalence of chronic kidney disease (CKD) and the risk factors of CKD in urban healthy population. Methods A total of 40377 subjects (24164 males and 16213 females) participated in this study. Body height, weight and blood pressure were measured, and morning urine and venous blood samples were collected for routine urine and blood tests with measurements of blood glucose, total cholesterol, high density lipoprotein (HDL), low-density lipoprotein (LDL), creatinine and uric acid. Results and Conclusion Using Japanese CKD Epidemiology Collaboration (J-EPI) equation and Chinese modified Modification of Diet in Renal Disease (C-MDRD) equation, the prevalence of CKD calculated was 3.9%and 6.3%in this population, respectively. The independent risk factors of CKD included an age over 60 years, high uric acid, and high blood glucose.

Aim To observe the protective effect of valsartan,benazepril and combination valsartan withbenazepril on cardiac damage in rats with chronic renal failure and explore the mechanism.Methods Forty Sprague Dawley male rats were selected,and were performed five-sixths nephrectomy to produce chronic renal failure model.Two weeks after the surgery,the rats were divided randomly into model group,valsartan group,benazepril group and both valsartan and benazepril group,and a sham group was established as control group.Systolic blood pressure,BUN and serum creatinine was measured at 10 week after operation,then all rats were killed to take the hearts for pathological histological observation.The transcription of endothelin-1(ET-1 )mRNA and nitricoxide synthase (eNOS-3) mRNA in myocardium was examined by hybridization in situ.Results Systolic pressure,heart weight,heart weight index,left ventricular weight mass(LVWM) and left ventricular weight mass index(LVWMI) in model group increased significantly at 10 week after operation. Systolic pressure,heart weight,heart weight index,LVWM and LVWMI decreased markedly in rats with five-sixths nephrectomy by valsartan and/or benazepril (P

AIM: To observe the therapeutic effect of valsartan on cardiac hypertrophy and expression of endothelin-1(ET-1) in myocardium of rats with chronic renal failure and explore the mechanism.METHODS: 24 Sprague Dawley male rats were selected,and performed five-sixths nephrectomy to produce chronic renal failure model.Two weeks after the surgery,the rats were randomly divided into model group,valsartan group,and a sham group was established serving as control group.Systolic blood pressure,BUN and serum creatinine were measured at ten weeks after operation,then the rats were sacrificed to take the hearts for pathological histological examination.Hybridization in situ was used to examine the transcription of ET-1 mRNA in myocardium.RESULTS: Systolic pressure,heart weight,heart weight index,left ventricular weight mass(LVM) and left ventricular weight mass index(LVMI) in model group increased significantly tenth week after operation.Systolic pressure,heart weight,heart weight index,LVM and LVMI were decreased markedly in rats with five-sixths nephrectomy by valsartan(P

AIM:To investigate the effects of angiotensin Ⅱ(AngⅡ)blockers on TNF-? and the relationship between TNF-? and proteinuria in patients with chronic glomerulonephritis(CGN).METHODS:32 patients examined by biopsy as primary CGN with proteinuria were treated by benazepril,valsartan or combination with benazepril and valsartan for 8 to 12 weeks respectively.The TNF-? levels in serum and urine,24 hours proteinuria quantity,and serum creatinine level were assayed and recorded respectively before and after 8 to 12 weeks therapy.RESULTS:The TNF-? levels in serum and urine and 24 hours proteinuria quantity were reduced significantly after therapy [(7.8?3.9)vs(5.0?1.6)fmol/mL,(11.9?6.8)vs(8.3?3.5)fmol/mL,(2.6?2.0)vs(1.0?0.5)g,respectively;P